The research data is preclinical and does not change the near-term delisting risk. Monitor for any Nasdaq compliance update or capital raise filing, as the company's listing status is the primary near-term catalyst.
Price Chart
Executive Summary
Silexion Therapeutics announced translational research data showing its SIL204 candidate leverages native serum lipids for intracellular delivery and robust KRAS oncogene knockdown. The press release is a scientific update with no financial data, guidance, or regulatory catalyst. The company remains under a Nasdaq delisting notice for bid price non-compliance, which overshadows this early-stage research milestone.
Key Facts
- SIL204 demonstrated use of native serum lipids for intracellular delivery in translational research
- SIL204 achieved robust KRAS oncogene knockdown in the study
- No financial results, guidance, or regulatory milestones were disclosed
- Company received a Nasdaq Staff letter on September 25, 2026 for bid price non-compliance
Financial Impact
No financial figures disclosed in the press release
Risk Factors
- Nasdaq delisting risk remains active with no compliance update in this release
- SIL204 is at an early translational stage with no clinical data or regulatory timeline provided
- No financial data or operational update to assess cash runway or dilution risk
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3369868 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | DEFA14A | $0.1538 | awaiting T+20 | — | $0.1750 (−13.78%) |
Oct 5, 2026 22d ago | DEF 14A | $0.2628 | awaiting T+20 | — | $0.1750 (+33.41%) |
Sep 30, 2026 27d ago | 8-K | $0.2770 | awaiting T+20 | — | $0.1750 (−36.82%) |
Sep 30, 2026 27d ago | Press Release | $0.2773 | awaiting T+20 | — | $0.1750 (+36.89%) |
Sep 29, 2026 28d ago | 8-K | $0.3180 $0.1650 | ▲ +48.11% | ▲ +48.77% | $0.1750 (+44.97%) |
Sep 29, 2026 28d ago | Press Release | $0.3184 $0.1657 | ▲ +47.96% | ▲ +48.67% | $0.1750 (+45.04%) |
Sep 28, 2026 29d ago | 8-K | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1750 (−29.55%) |
Sep 28, 2026 29d ago | Press Release | $0.2484 $0.1746 | ▼ −29.71% | ▼ −29.68% | $0.1750 (−29.55%) |
Sep 25, 2026 4w ago | 8-K | $0.2484 $0.1746 | ▲ +29.71% | ▲ +29.68% | $0.1750 (+29.55%) |
Aug 14, 2026 10w ago | 8-K | $0.4202 $0.3854 | ▲ +8.28% | ▲ +6.29% | $0.1750 (+58.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers